Disposition and metabolism of safinamide, a novel drug for parkinson's disease, in healthy male volunteers

Pharmacology

Volumn 92, Issue 3-4, 2013, Pages 207-216

  Leuratti, Chiara ^a   Sardina, Marco ^a   Ventura, Paolo ^a   Assandri, Alessandro ^a   Müller, Markus ^a   Brunner, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Metabolism; Monoamine oxidase B inhibitor; Pharmacokinetics; Safinamide

Indexed keywords

GLUCURONIDE; SAFINAMIDE; SAFINAMIDE C 14; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORAL CLEARANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ALANINE; BENZYLAMINES; FECES; HEALTHY VOLUNTEERS; HUMANS; MALE; PARKINSON DISEASE; YOUNG ADULT;

EID: 84885492160     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000354805     Document Type: Article

References (20)

1. Fariello RG. Safinamide (review). Neurotherapeutics 2007; 4: 110-116
2. Singer C. Managing the patient with newly diagnosed Parkinson disease. Cleve Clin J Med 2012; 79(suppl 2):S3-S7
3. Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013; 19: 508-514
4. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006; 67(7suppl 2):S18-S23
5. Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 2011; 25: 1061-1071
6. Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L, Mazzanti M, Mancinelli E, Varasi M, Fariello RG. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 1999; 288: 1151-1159
7. Pevarello P, Amici R, Bonsignori A, Caccia C, Amici R, McArthur RA, Fariello RG, Salvati P, Varasi M. Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsivants. Bioorg Med Chem Lett 1999; 9: 2521-2524
8. Binda C, Milczek EM, Bonivento D, Wang J, Mattevi A, Edmondson DE. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies (review). Curr Top Med Chem 2011; 11: 2788-2796
9. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother 2010; 11: 2261-2268
10. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 2008; 17: 1115-1125
11. Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, Giuliani R, Anand R; Study 015 Investigators: A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 106-112
12. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, Lucini V, Giuliani R, Anand R; Study 017 Investigators: Longterm efficacy and safety of safinamide as addon therapy in early Parkinson's disease. Eur J Neurol 2013; 20: 271-280
13. Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krosser S, Kovar A. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther 2012; 92: 450-457
14. Di Stefano AFD, Rusca A. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 2011; 384: 505-515
15. Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol 2003; 26: 213-217
16. Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004; 50: 77-85
17. Janssens de Varebeke P, Cavalier R, David-Remacle M, Youdin MBH. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem 1988; 50: 1011-1016
18. Youdim MBH. Platelet monoamine oxidase B. use and misuse. Experientia 1988; 44: 137-141
19. Bauer M, Bliesath H, Leuratti C, Lackner E, Dieterle W, Muller M, Brunner M. Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers. Pharmacology 2010; 86: 297-305
20. Krosser S, Marquet A, Gallemann D, Wolna P, Fauchoux N, Hermann R, Johne A. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos 2012; 33: 550-559